ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber Sells 16,438 Shares

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 16,438 shares of the stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $2.51, for a total transaction of $41,259.38. Following the completion of the transaction, the senior vice president now owns 155,194 shares of the company’s stock, valued at approximately $389,536.94. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

ProKidney Trading Down 7.0 %

Shares of NASDAQ PROK opened at $2.53 on Wednesday. The stock has a market cap of $580.24 million, a price-to-earnings ratio of -4.44 and a beta of 1.08. ProKidney Corp. has a 52 week low of $1.12 and a 52 week high of $13.51. The company’s 50-day moving average price is $1.63 and its 200 day moving average price is $1.74.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. As a group, research analysts expect that ProKidney Corp. will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On ProKidney

A number of large investors have recently added to or reduced their stakes in PROK. SG Americas Securities LLC acquired a new stake in shares of ProKidney during the 3rd quarter worth about $78,000. Jump Financial LLC acquired a new stake in shares of ProKidney during the 3rd quarter worth about $216,000. Finally, Federated Hermes Inc. boosted its stake in shares of ProKidney by 10,984.7% during the 4th quarter. Federated Hermes Inc. now owns 113,286 shares of the company’s stock worth $202,000 after purchasing an additional 112,264 shares during the last quarter. 51.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on PROK shares. Bank of America downgraded shares of ProKidney from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd. Morgan Stanley started coverage on shares of ProKidney in a research note on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price objective on the stock.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.